Wie eine Krankheit gemacht wird: Female Sexual Dysfunction

Literatur

• 1 Bancroft J. The medicalization of female sexual dysfunction: the need for caution. Arch Sex Behav 2002; 31: 451-455 (Erstveröffentlichung in deutscher Sprache: Die Medikalisierung sexueller Probleme von Frauen. Z Sexualforsch 2000; 13: 69-76)
• 2 Bancroft J, Graham C A, McCord C. Conceptualizing women’s sexual problems.  J Sex Marital Ther. 2001;  27 95-103
• 3 Basson R, Berman J, Burnett A, Derogatis L, Ferguson D, Fourcroy J e tal. Report of the International Consensus Development Conference on Female Sexual Dysfunction: definitions and classifications.  Urology. 2000;  163 888-893
• 4 Berman J, Berman L, Goldstein I. Female sexual dysfunction: incidence, pathophysiology, evaluation, and treatment options.  Urology. 1999;  54 385-391
• 5 Berman J, Berman L, Lin H, Flaherty E, Lahey N, Goldstein I e tal. Effect of sildenafil on subjective and physiologic parameters of the female sexual response in women with sexual arousal disorder.  J Sex Marital Ther. 2001;  27 411-420
• 6 Berman J, Berman L, Toler S, Gill J, Haughie S. Efficacy and tolerability of sildenafil citrate in women with sexual arousal disorder: a double-blind placebo-controlled study [abstract]. Annual meeting of the International Society for the Study of Women’s Sexual Health, 10. bis 13. Oktober 2002; 49
• 7 Cooke R. There’s gold in them there pills . . . Observer, 27. Oktober 2002
• 8 Kaschak E, Tiefer L. A new view of women’s sexual problems. New York u. a.: Haworth Press 2001
• 9 Laumann E, Paik A, Rosen R. Sexual dysfunction in the United States: prevalence and predictors. J Am Med Assoc 1999; 281: 537-544 (Erratum in: J Am Med Assoc 1999; 281: 1174)
• 10 Moynihan R, Heath I, Henry D. Selling sickness: the pharmaceutical industry and disease mongering.  Br Med J. 2002;  324 886-891
• 11 Park K, Goldstein I, Andry C, Siroky M, Krane R, Azadzoi K. Vasculogenic female sexual dysfunction: the hemodynamic basis for vaginal engorgement insufficiency and clitoral erectile insufficiency.  Int J Impotence Res. 1997;  9 27-37
• 12 Rosen R C, O’Leary M P. The Cape Cod conference: sexual function assessment in clinical trials: May 30-31, 1992.  Int J Impotence Res. 1998;  10 (Suppl. 2) 1-142
• 13 Tiefer L. The medicalization of sexuality: conceptual, normative, and professional issues.  Ann Rev Sex Res. 1996;  7 252-282
• 14 Tiefer L. Sexology and the parmaceutical industry: the threat of co-optation.  J Sex Res. 2000;  37 273-283
• 15 Tiefer L. Arriving at a „new view” of women’s sexual problems: Background, theory, and activism. In: Kaschak und Tiefer 2001: 63-98